Skip to contentE
Estrella Immunopharma, Inc.
E
ESLAWEstrella Immunopharma, Inc. Released Nov 13, 2026, after the close
10-Q filed Nov 16, 2026, 47 days after period end · 0001213900-26-120047
Q3 2026 · 10-Q
Revenue—
Net Income-$7.38M-$7.38MN/M vs Q3 2025N/M vs Q2 2026 EPS Diluted
No earnings release is on file for this quarter. Its figures came with the 10-Q.
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Estrella Immunopharma, Inc. · CIK 1844417 · Engraved from SEC EDGAR
-$0.17-$0.17N/M vs Q3 2025N/M vs Q2 2026 Operating Income-$7,496,223N/M Operating Cash Flowderived-$217,212N/M Filing lag
ended Sep 30, 2026 · filed Nov 16, 2026 · 47 d after period end